Please login to the form below

Not currently logged in
Email:
Password:

Amgen finance VP joins True North Therapeutics

Pamela Wapnick appointed as chief financial officer

California-based True North Therapeutics has appointed Pamela Wapnick as its new chief financial officer.

Wapnick joins the rare diseases clinical stage biopharmaceutical company from Amgen, where she most recently served as vice president of finance.

Prior to this, Wapnick had corporate finance responsibility for Amgen's global research and development activities, and has served as vice president and treasurer of Amgen.

She brings over 25 years of international business and finance experience to True North, including senior financial management positions at Delphi Corporation, Federal Mogul Corporation and General Motors Corporation.

Nancy Stagliano, chief executive officer of True North, said: “I am pleased to announce Pam's appointment to the position of chief financial officer as a member of our management team.

“Her breadth of experience in corporate finance and treasury within the biotechnology industry, including nearly 10 years and Amgen, will serve us well as we continue to advance True North's pipeline of novel product candidates.”

3rd August 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics